Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xspray Pharma AB ( (SE:XSPRAY) ) has provided an update.
Xspray Pharma has signed a license agreement with Handa Therapeutics, allowing Handa to commercialize a dasatinib product in the US and selected Asian markets. This agreement marks Xspray’s first out-licensing from its patent portfolio, highlighting the value of its intellectual property and supporting its strategy to develop improved PKI drugs. The deal ensures that Xspray’s launch of Dasynoc remains unaffected by regulatory exclusivities related to Handa’s product, positioning Dasynoc as a premium offering in the dasatinib market segment.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in the development of improved protein kinase inhibitors (PKIs) for cancer treatment using its patented HyNap technology. The company aims to lead the oncology market segment with its innovative drug candidates, including Dasynoc, which is under FDA review, and other optimized versions of existing cancer drugs.
Average Trading Volume: 30,615
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.91B
For an in-depth examination of XSPRAY stock, go to TipRanks’ Overview page.